126 related articles for article (PubMed ID: 38623978)
1. Primary Pulmonary Lymphoepithelioma-like Carcinoma: A Case Report Utilizing Camrelizumab and Anlotinib for Prolonged Survival.
Lei S; Tian S; Lu S; Qing Z; Long J; Li L; Yang D
Anticancer Agents Med Chem; 2024 Apr; ():. PubMed ID: 38623978
[TBL] [Abstract][Full Text] [Related]
2. Case Report: Anlotinib Reverses Nivolumab Resistance in Advanced Primary Pulmonary Lymphoepithelioma-Like Carcinoma With FGFR3 Gene Amplification.
Liu Y; Long L; Liu J; Zhu L; Luo F
Front Oncol; 2021; 11():749682. PubMed ID: 34692530
[TBL] [Abstract][Full Text] [Related]
3. [Clinical Analysis of Primary Pulmonary Lymphoepithelioma-like Carcinoma in 8 Patients].
Zhao H; Chen J
Zhongguo Fei Ai Za Zhi; 2020 Mar; 23(3):168-175. PubMed ID: 32209185
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathological characteristics and cancer-specific prognosis of primary pulmonary lymphoepithelioma-like carcinoma: a population study of the US SEER database and a Chinese hospital.
Zhang Q; Dai Y; Jin L; Shi S; Liu C; Rong R; Sun W; Dai S; Kong H; Xie W
Front Oncol; 2023; 13():1103169. PubMed ID: 37274245
[TBL] [Abstract][Full Text] [Related]
5. Molecular and Clinical Characteristics of Primary Pulmonary Lymphoepithelioma-Like Carcinoma.
Fan Y; Shan Q; Gong J; Qin J; Lu H
Front Mol Biosci; 2021; 8():736940. PubMed ID: 34760925
[No Abstract] [Full Text] [Related]
6. Primary pulmonary lymphoepithelioma-like carcinoma.
Fan Y; Li C; Qin J; Lu H
Med Oncol; 2020 Mar; 37(3):20. PubMed ID: 32146584
[TBL] [Abstract][Full Text] [Related]
7. Immune Checkpoint Blockade Therapy May Be a Feasible Option for Primary Pulmonary Lymphoepithelioma-like Carcinoma.
Wu Z; Xian X; Wang K; Cheng D; Li W; Chen B
Front Oncol; 2021; 11():626566. PubMed ID: 33981599
[TBL] [Abstract][Full Text] [Related]
8. Analysis of clinical features, treatment, and prognosis of primary Xlymphoepithelioma-like carcinoma of the lung.
Hu HY; Long L; Dai SA; Yan GQ; Huang Y; He J
Eur Rev Med Pharmacol Sci; 2022 Dec; 26(24):9416-9425. PubMed ID: 36591850
[TBL] [Abstract][Full Text] [Related]
9. Anlotinib improved the reactive cutaneous capillary endothelial proliferation induced by camrelizumab: a case report.
Wu R; Ju Y; Long T; Su Z; Zhu G; Liu S
Transl Cancer Res; 2022 Aug; 11(8):2940-2945. PubMed ID: 36093549
[TBL] [Abstract][Full Text] [Related]
10. Primary pulmonary lymphoepithelioma-like carcinoma in Singapore.
Tay CK; Chua YC; Takano A; Min Chee MY; Lim WT; Lim C; Koh MS
Ann Thorac Med; 2018; 13(1):30-35. PubMed ID: 29387253
[TBL] [Abstract][Full Text] [Related]
11. Case Report: Chemotherapy-free treatment with camrelizumab and anlotinib for elderly patients with
Qi W; Xi D; Bai Y; Liu L; Ma Y; Yin Z; Chen H
Front Pharmacol; 2023; 14():1026135. PubMed ID: 36713848
[No Abstract] [Full Text] [Related]
12. Anlotinib combined with anti-PD-1 antibody, camrelizumab for advanced NSCLCs after multiple lines treatment: An open-label, dose escalation and expansion study.
Zhou N; Jiang M; Li T; Zhu J; Liu K; Hou H; Zhang X
Lung Cancer; 2021 Oct; 160():111-117. PubMed ID: 34482102
[TBL] [Abstract][Full Text] [Related]
13. Primary pulmonary lymphoepithelioma-like carcinoma treated with immunotherapy: A case report and literature review.
Archwamety A; Ruangchira-Urai R; Akewanlop C; Korphaisarn K
Thorac Cancer; 2022 Sep; 13(17):2539-2541. PubMed ID: 35830974
[TBL] [Abstract][Full Text] [Related]
14. Anti-angiogenic therapy for advanced primary pulmonary lymphoepithelioma-like carcinoma: a retrospective multicenter study.
Bao H; Ma LZ; Zhao C; Yu M; Zhang B; Zhang J; Peng G; Lin X; Fang Y; Bao H; Ma S
J Cancer Res Clin Oncol; 2023 Mar; 149(3):1185-1193. PubMed ID: 35377040
[TBL] [Abstract][Full Text] [Related]
15. Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study.
Huang J; Xu J; Chen Y; Zhuang W; Zhang Y; Chen Z; Chen J; Zhang H; Niu Z; Fan Q; Lin L; Gu K; Liu Y; Ba Y; Miao Z; Jiang X; Zeng M; Chen J; Fu Z; Gan L; Wang J; Zhan X; Liu T; Li Z; Shen L; Shu Y; Zhang T; Yang Q; Zou J;
Lancet Oncol; 2020 Jun; 21(6):832-842. PubMed ID: 32416073
[TBL] [Abstract][Full Text] [Related]
16. Primary pulmonary lymphoepithelioma-like carcinoma misdiagnosed as lung squamous cell carcinoma: A case report.
Yin CJ; Wang GJ; Su XM; Li D
World J Clin Cases; 2023 Nov; 11(32):7876-7880. PubMed ID: 38073692
[TBL] [Abstract][Full Text] [Related]
17. Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma: The ESCORT-1st Randomized Clinical Trial.
Luo H; Lu J; Bai Y; Mao T; Wang J; Fan Q; Zhang Y; Zhao K; Chen Z; Gao S; Li J; Fu Z; Gu K; Liu Z; Wu L; Zhang X; Feng J; Niu Z; Ba Y; Zhang H; Liu Y; Zhang L; Min X; Huang J; Cheng Y; Wang D; Shen Y; Yang Q; Zou J; Xu RH;
JAMA; 2021 Sep; 326(10):916-925. PubMed ID: 34519801
[TBL] [Abstract][Full Text] [Related]
18. Immune checkpoint inhibitors
Liu S; Dou L; Li S
Therap Adv Gastroenterol; 2024; 17():17562848241233134. PubMed ID: 38425370
[TBL] [Abstract][Full Text] [Related]
19. First-line platinum-based chemotherapy and survival outcomes in locally advanced or metastatic pulmonary lymphoepithelioma-like carcinoma.
Lin Z; Fu S; Zhou Y; Zhang X; Chen C; He LN; Li H; Wang Y; Chen T; Zhang L; Hong S
Lung Cancer; 2019 Nov; 137():100-107. PubMed ID: 31568886
[TBL] [Abstract][Full Text] [Related]
20. Development of a haematological indices-based nomogram for prognostic prediction and immunotherapy response assessment in primary pulmonary lymphoepithelioma-like carcinoma patients.
Sheng H; He X; Chen Z; Huang K; Yang J; Wei X; Mao M
Transl Lung Cancer Res; 2024 Mar; 13(3):453-464. PubMed ID: 38601436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
